First-line Treatment Options for mCRPC


Dr. Morgans discusses first-line therapy options for mCRPC and her approach to deciding between different treatment options.

Alicia Morgans, MD, MPH: The first-line options for treatment of metastatic CRPC [castration-resistant prostate cancer] are numerous, and we make our decisions based on the treatments the patient has had prior, either for nonmetastatic CRPC or for metastatic hormone-sensitive prostate cancer.

For example, patients who have had treatment with intensified ADT [androgen deprivation therapy] for metastatic hormone-sensitive prostate cancer with abiraterone, enzalutamide, or apalutamide should receive a different approach for metastatic CRPC. Usually, it’s going to be a docetaxel chemotherapy and an ADT combination in that first-line setting. If a patient has had docetaxel in the metastatic hormone-sensitive setting, they would typically proceed with a shift in the mechanism of action to treatment with ADT plus abiraterone or enzalutamide.

For patients who have had treatment for nonmetastatic CRPC, we only have those AR [androgen receptor]–targeted agents as options for intensification with our ADT, and those patients typically get treatment with chemotherapy. It’s important to remember that there are other options; for patients who have relatively slowly progressing and asymptomatic disease, sipuleucel-T is an option. For patients who have DRD alterations, they could potentially get treatment with olaparib if they had previous treatment with an AR-targeted treatment combination with ADT. Finally, if patients have significant bone metastases and pain, they could even get treatment with radium.

There are a lot of options, and we make our treatment decisions for first-line metastatic CRPC based on the combinations of therapies the patient has had in the past.

Transcript edited for clarity.

A 70-Year-Old Man with Metastatic Castration-Resistant Prostate Cancer

May 2017

Initial presentation

A 70-year-old man presents with nocturia and decreased appetite

Clinical workup

  1. PMH: Unremarkable
  2. PE: DRE, enlarged prostate
  3. TRUS and biopsy revealed adenocarcinoma of the prostate gland, Gleason score 9 [5+4]
  4. CT showed minimal nodal involvement
  5. PSA 42 ng/mL, LDH 404 U/L
  6. His ECOG PS is 1


  1. Patient started on ADT with initial PSA response 12 ng/mL

December 2017

  1. Patient complained of right hip pain and abdomen pain
  2. Imaging with CT and bone scan showed 2 metastatic bone lesions in the pelvis and diffuse liver lesions
  3. PSA 30 ng/mL; Hb 9.4 g/dL; ANC 1.5
  4. Patient started on docetaxel, 6 cycles completed
  5. Follow-up imaging showed stable disease

November 2018

  1. PSA 40 ng/mL
  2. Routine imaging shows new metastatic bone lesions in the pelvis
  3. Patient started on abiraterone and prednisone, after 6 months he has a restaging scan which shows continued progression of disease

January 2019

  1. Patient had a 68Ga-PSMA-11 scan when screening for the VISION trial which shows several positive metastatic lesions in the pelvis and liver metastases
  2. He qualified on screening and enrolled in a clinical trial and treated with 177Lu-PSMA-617 as per the VISION protocol (7.4 Gbq [100 mCi] every 6 weeks for 4-6 cycles)
Related Videos
Experts on prostate cancer
Expert on prostate cancer
Experts on prostate cancer
Expert on prostate cancer
Experts on prostate cancer
Experts on prostate cancer
Experts on prostate cancer
Related Content